Item Type | Name |
Academic Article
|
Tumour necrosis factor as an autocrine tumour growth factor for chronic B-cell malignancies.
|
Academic Article
|
Effects of tumour necrosis factor and alpha interferon on chronic B cell malignancies.
|
Academic Article
|
In vitro analysis of the interactions of recombinant IL-2 with regenerating lymphoid and myeloid cells after allogeneic marrow transplantation.
|
Academic Article
|
Gene transfer and bone marrow transplantation.
|
Academic Article
|
Production of genetically modified Epstein-Barr virus-specific cytotoxic T cells for adoptive transfer to patients at high risk of EBV-associated lymphoproliferative disease.
|
Academic Article
|
Direct demonstration that autologous bone marrow transplantation for solid tumors can return a multiplicity of tumorigenic cells.
|
Academic Article
|
XomaZyme-CD5 immunotoxin in conjunction with partial T cell depletion for prevention of graft rejection and graft-versus-host disease after bone marrow transplantation from matched unrelated donors.
|
Academic Article
|
T cell receptor repertoire of CD4+ and CD8+ T cell subsets in the allogeneic bone marrow transplant recipient.
|
Academic Article
|
Response of steroid-resistant graft-versus-host disease to lymphoblast antibody CBL1.
|
Academic Article
|
Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation.
|
Academic Article
|
Administration of neomycin-resistance-gene-marked EBV-specific cytotoxic T lymphocytes to recipients of mismatched-related or phenotypically similar unrelated donor marrow grafts.
|
Academic Article
|
Gene marking and autologous bone marrow transplantation.
|
Academic Article
|
Cytokine gene transfer in the therapy of malignancy.
|
Academic Article
|
Assessment of the efficacy of purging by using gene marked autologous marrow transplantation for children with AML in first complete remission.
|
Academic Article
|
Donor T cells to treat EBV-associated lymphoma.
|
Academic Article
|
Gene marking after bone marrow transplantation.
|
Academic Article
|
Gene transfer into human hemopoietic progenitor cells.
|
Academic Article
|
Use of double marking with retroviral vectors to determine rate of reconstitution of untreated and cytokine expanded CD34+ selected marrow cells in patients undergoing autologous bone marrow transplantation.
|
Academic Article
|
Early identification of Epstein-Barr virus-associated post-transplantation lymphoproliferative disease.
|
Academic Article
|
Measuring gene-transfer efficiency.
|
Academic Article
|
Adoptive cellular immunotherapy for EBV lymphoproliferative disease.
|
Academic Article
|
EBV specific CTL: a model for immune therapy.
|
Academic Article
|
Immunotherapy for Epstein-Barr virus-associated cancers.
|
Academic Article
|
Transfer of marker genes into hemopoietic progenitor cells.
|
Academic Article
|
Anti-pan T lymphocyte ricin A chain immunotoxin (H65-RTA) and methylprednisolone for acute GVHD prophylaxis following allogeneic BMT from HLA-identical sibling donors.
|
Academic Article
|
Increased transduction efficiency of primary hematopoietic cells by physical colocalization of retrovirus and target cells.
|
Academic Article
|
Gene therapy of pediatric leukemia.
|
Academic Article
|
Portal venous Doppler findings in a bone marrow transplant patient with cardiac tamponade.
|
Academic Article
|
Gene and cell transfer for specific immunotherapy.
|
Academic Article
|
Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients.
|
Academic Article
|
Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes.
|
Academic Article
|
Gamma delta T lymphocyte regeneration after T lymphocyte-depleted bone marrow transplantation from mismatched family members or matched unrelated donors.
|
Academic Article
|
Use of gene marking in bone marrow transplantation.
|
Academic Article
|
Lymphoproliferative disorders involving Epstein-Barr virus after hemopoietic stem cell transplantation.
|
Academic Article
|
Adoptive immunotherapy of EBV-associated malignancies with EBV-specific cytotoxic T-cell lines.
|
Academic Article
|
Preventing Epstein-Barr virus lymphoproliferative disease after bone marrow transplantation.
|
Academic Article
|
Generation of EBV-specific CD4+ cytotoxic T cells from virus naive individuals.
|
Academic Article
|
Treatment of Epstein-Barr virus-associated malignancies with specific T cells.
|
Academic Article
|
Gene transfer for the therapy of hematologic malignancy.
|
Academic Article
|
Immunotherapy for Hodgkin's disease.
|
Academic Article
|
An Epstein-Barr virus deletion mutant associated with fatal lymphoproliferative disease unresponsive to therapy with virus-specific CTLs.
|
Academic Article
|
Large-scale expansion of dendritic cell-primed polyclonal human cytotoxic T-lymphocyte lines using lymphoblastoid cell lines for adoptive immunotherapy.
|
Academic Article
|
Is retroviral gene marking too dangerous to use?
|
Academic Article
|
Upper airway obstruction and pulmonary abnormalities due to lymphoproliferative disease following bone marrow transplantation in children.
|
Academic Article
|
The use of cytotoxic t cells for the prevention and treatment of epstein-barr virus induced lymphoma in transplant recipients.
|
Academic Article
|
Treatment of relapsed Hodgkin's disease using EBV-specific cytotoxic T cells.
|
Academic Article
|
A strategy for treatment of Epstein-Barr virus-positive Hodgkin's disease by targeting interleukin 12 to the tumor environment using tumor antigen-specific T cells.
|
Academic Article
|
Transfusion-related acute lung injury (TRALI) following allogeneic stem cell transplant for acute myeloid leukemia.
|
Academic Article
|
Evidence for the presentation of major histocompatibility complex class I-restricted Epstein-Barr virus nuclear antigen 1 peptides to CD8+ T lymphocytes.
|
Academic Article
|
CD20 monoclonal antibody (rituximab) for therapy of Epstein-Barr virus lymphoma after hemopoietic stem-cell transplantation.
|
Academic Article
|
Treatment of Epstein-Barr virus lymphoproliferative disease after hematopoietic stem-cell transplantation with hydroxyurea and cytotoxic T-cell lymphocytes.
|
Academic Article
|
Treatment of nasopharyngeal carcinoma with Epstein-Barr virus--specific T lymphocytes.
|
Academic Article
|
An inducible caspase 9 safety switch for T-cell therapy.
|
Academic Article
|
Gene-marking studies of hematopoietic cells.
|
Academic Article
|
Graft-versus-host reactions and bone-marrow transplantation.
|
Academic Article
|
Gene therapy for paediatric leukaemia.
|
Academic Article
|
Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the prevention and treatment of EBV-associated post-transplant lymphomas.
|
Academic Article
|
Current status of genetic modification of T cells for cancer treatment.
|
Academic Article
|
Hematopoietic and immunomodulatory effects of lytic CD45 monoclonal antibodies in patients with hematologic malignancy.
|
Academic Article
|
Selective depletion of donor alloreactive T cells without loss of antiviral or antileukemic responses.
|
Academic Article
|
Immunotherapy of high-risk acute leukemia with a recipient (autologous) vaccine expressing transgenic human CD40L and IL-2 after chemotherapy and allogeneic stem cell transplantation.
|
Academic Article
|
Adoptive immunotherapy with allodepleted donor T-cells improves immune reconstitution after haploidentical stem cell transplantation.
|
Academic Article
|
Adoptive T-cell therapy for EBV-associated post-transplant lymphoproliferative disease.
|
Academic Article
|
Identification of HLA-DP3-restricted peptides from EBNA1 recognized by CD4(+) T cells.
|
Academic Article
|
Comparable outcomes of matched-related and alternative donor stem cell transplantation for pediatric severe aplastic anemia.
|
Academic Article
|
Immunotherapy for Epstein-Barr virus-associated cancers in children.
|
Academic Article
|
Epstein Barr virus specific cytotoxic T lymphocytes expressing the anti-CD30zeta artificial chimeric T-cell receptor for immunotherapy of Hodgkin disease.
|
Academic Article
|
Identification of hexon-specific CD4 and CD8 T-cell epitopes for vaccine and immunotherapy.
|
Academic Article
|
Adoptive cellular immunotherapy for viral diseases.
|
Academic Article
|
The generation and characterization of LMP2-specific CTLs for use as adoptive transfer from patients with relapsed EBV-positive Hodgkin disease.
|
Academic Article
|
Antitumor activity of EBV-specific T lymphocytes transduced with a dominant negative TGF-beta receptor.
|
Academic Article
|
Cytotoxic T lymphocytes directed to the preferentially expressed antigen of melanoma (PRAME) target chronic myeloid leukemia.
|
Academic Article
|
Flanking-sequence exponential anchored-polymerase chain reaction amplification: a sensitive and highly specific method for detecting retroviral integrant-host-junction sequences.
|
Academic Article
|
Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma.
|
Academic Article
|
Adoptive T-cell therapy for Epstein-Barr virus-positive Hodgkin's disease.
|
Academic Article
|
Genetic manipulation of tumor-specific cytotoxic T lymphocytes to restore responsiveness to IL-7.
|
Academic Article
|
T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model.
|
Academic Article
|
Functionally active virus-specific T cells that target CMV, adenovirus, and EBV can be expanded from naive T-cell populations in cord blood and will target a range of viral epitopes.
|
Academic Article
|
Cytotoxic T lymphocyte therapy with donor T cells prevents and treats adenovirus and Epstein-Barr virus infections after haploidentical and matched unrelated stem cell transplantation.
|
Academic Article
|
Characteristics of T-cell receptor repertoire and myelin-reactive T cells reconstituted from autologous haematopoietic stem-cell grafts in multiple sclerosis.
|
Academic Article
|
Adoptive immunotherapy for posttransplantation viral infections.
|
Academic Article
|
T-cell-based therapies for malignancy and infection in childhood.
|
Academic Article
|
Antigen-specific cytotoxic T lymphocytes can target chemoresistant side-population tumor cells in Hodgkin lymphoma.
|
Academic Article
|
Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety.
|
Academic Article
|
Options for T-cell based therapies.
|
Academic Article
|
Cellular therapy of Epstein-Barr-virus-associated post-transplant lymphoproliferative disease.
|
Academic Article
|
Homeostatic action of interleukin-4 on endogenous and recombinant interleukin-2-induced activated killer cell function.
|
Academic Article
|
Characterization and treatment of chronic active Epstein-Barr virus disease: a 28-year experience in the United States.
|
Academic Article
|
T-cell immunotherapy for adenoviral infections of stem-cell transplant recipients.
|
Academic Article
|
Expansion of T cells targeting multiple antigens of cytomegalovirus, Epstein-Barr virus and adenovirus to provide broad antiviral specificity after stem cell transplantation.
|
Academic Article
|
Comparison of the efficiency of transduction of leukemic cells by fiber-modified adenoviruses.
|
Academic Article
|
Possible mechanism of action of interferon alpha in chronic B-cell malignancies.
|
Academic Article
|
Assessing the safety of cytotoxic T lymphocytes transduced with a dominant negative transforming growth factor-beta receptor.
|
Academic Article
|
Inducible apoptosis as a safety switch for adoptive cell therapy.
|
Academic Article
|
Commentary on journal of immunotherapy paper by melenhorst et al.
|
Academic Article
|
A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells.
|
Academic Article
|
T lymphocytes redirected against the kappa light chain of human immunoglobulin efficiently kill mature B lymphocyte-derived malignant cells.
|
Academic Article
|
Endogenously generated activated killer cells circulate after autologous and allogeneic marrow transplantation but not after chemotherapy.
|
Academic Article
|
Characterization of latent membrane protein 2 specificity in CTL lines from patients with EBV-positive nasopharyngeal carcinoma and lymphoma.
|
Academic Article
|
Quantification of a low cellular immune response to aid in identification of pediatric liver transplant recipients at high-risk for EBV infection.
|
Academic Article
|
Rapidly generated multivirus-specific cytotoxic T lymphocytes for the prophylaxis and treatment of viral infections.
|
Academic Article
|
Administration of latent membrane protein 2-specific cytotoxic T lymphocytes to patients with relapsed Epstein-Barr virus-positive lymphoma.
|
Academic Article
|
Treatment of solid organ transplant recipients with autologous Epstein Barr virus-specific cytotoxic T lymphocytes (CTLs).
|
Academic Article
|
T cell therapies.
|
Academic Article
|
Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals.
|
Academic Article
|
T cell therapy in allogeneic stem cell transplantation.
|
Academic Article
|
Reconstitution of adenovirus-specific cell-mediated immunity in pediatric patients after hematopoietic stem cell transplantation.
|
Academic Article
|
Regression of experimental medulloblastoma following transfer of HER2-specific T cells.
|
Academic Article
|
Co-expression of cytokine and suicide genes to enhance the activity and safety of tumor-specific cytotoxic T lymphocytes.
|
Academic Article
|
Inducible caspase 9 suicide gene to improve the safety of allodepleted T cells after haploidentical stem cell transplantation.
|
Academic Article
|
Malignant plasma cells are sensitive to LAK cell lysis: pre-clinical and clinical studies of interleukin 2 in the treatment of multiple myeloma.
|
Academic Article
|
Exploiting cytokine secretion to rapidly produce multivirus-specific T cells for adoptive immunotherapy.
|
Academic Article
|
The clone ranger?
|
Academic Article
|
Immunotherapy targeting EBV-expressing lymphoproliferative diseases.
|
Academic Article
|
Enhancing the in vivo expansion of adoptively transferred EBV-specific CTL with lymphodepleting CD45 monoclonal antibodies in NPC patients.
|
Academic Article
|
Gamma-interferon and tumor necrosis factor production after bone marrow transplantation is augmented by exposure to marrow fibroblasts infected with cytomegalovirus.
|
Academic Article
|
Immunotherapy for osteosarcoma: genetic modification of T cells overcomes low levels of tumor antigen expression.
|
Academic Article
|
Generation of Epstein-Barr virus-specific cytotoxic T lymphocytes resistant to the immunosuppressive drug tacrolimus (FK506).
|
Academic Article
|
How I treat EBV lymphoproliferation.
|
Academic Article
|
Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients.
|
Academic Article
|
Selective depletion of a minor subpopulation of B-chronic lymphocytic leukemia cells is followed by a delayed but progressive loss of bulk tumor cells and disease regression.
|
Academic Article
|
HER2-specific T cells target primary glioblastoma stem cells and induce regression of autologous experimental tumors.
|
Academic Article
|
Selective elimination of a chemoresistant side population of B-CLL cells by cytotoxic T lymphocytes in subjects receiving an autologous hCD40L/IL-2 tumor vaccine.
|
Academic Article
|
Effects of interferon alpha on autocrine growth factor loops in B lymphoproliferative disorders.
|
Academic Article
|
Transduction of CD34(+) and CD34(-)/lin(-) hemopoietic progenitors by lentivirus vectors.
|
Academic Article
|
Adverse events following infusion of T cells for adoptive immunotherapy: a 10-year experience.
|
Academic Article
|
Accelerated production of antigen-specific T cells for preclinical and clinical applications using gas-permeable rapid expansion cultureware (G-Rex).
|
Academic Article
|
Allogeneic virus-specific T cells with HLA alloreactivity do not produce GVHD in human subjects.
|
Academic Article
|
Crosstalk between medulloblastoma cells and endothelium triggers a strong chemotactic signal recruiting T lymphocytes to the tumor microenvironment.
|
Academic Article
|
Getting personal with melanoma.
|
Academic Article
|
Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma.
|
Academic Article
|
Adoptive transfer of EBV-specific T cells results in sustained clinical responses in patients with locoregional nasopharyngeal carcinoma.
|
Academic Article
|
Replication-competent retroviruses in gene-modified T cells used in clinical trials: is it time to revise the testing requirements?
|
Academic Article
|
In vivo induction of gamma interferon and tumor necrosis factor by interleukin-2 infusion following intensive chemotherapy or autologous marrow transplantation.
|
Academic Article
|
Genetic modification of T cells.
|
Academic Article
|
High-avidity cytotoxic T lymphocytes specific for a new PRAME-derived peptide can target leukemic and leukemic-precursor cells.
|
Academic Article
|
Ex vivo gene transfer for improved adoptive immunotherapy of cancer.
|
Academic Article
|
CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients.
|
Academic Article
|
Immunotherapeutic strategies to prevent and treat human herpesvirus 6 reactivation after allogeneic stem cell transplantation.
|
Academic Article
|
Definitions of histocompatibility typing terms: Harmonization of Histocompatibility Typing Terms Working Group.
|
Academic Article
|
Improving T-cell therapy for relapsed EBV-negative Hodgkin lymphoma by targeting upregulated MAGE-A4.
|
Academic Article
|
Cytotoxic T lymphocytes simultaneously targeting multiple tumor-associated antigens to treat EBV negative lymphoma.
|
Academic Article
|
Aggressive peripheral CD70-positive T-cell lymphoma associated with severe chronic active EBV infection.
|
Academic Article
|
Pharmacotherapy versus T lymphocytes for CMV.
|
Academic Article
|
Enhancement of monoclonal antibody dependent cell mediated cytotoxicity by IL2 and GM-CSF.
|
Academic Article
|
Effects of recombinant interleukin-2 administration on cytotoxic function following high-dose chemo-radiotherapy for hematological malignancy.
|
Academic Article
|
Generation of polyclonal CMV-specific T cells for the adoptive immunotherapy of glioblastoma.
|
Academic Article
|
T-cell therapy in the treatment of post-transplant lymphoproliferative disease.
|
Academic Article
|
Interleukin 15 provides relief to CTLs from regulatory T cell-mediated inhibition: implications for adoptive T cell-based therapies for lymphoma.
|
Academic Article
|
Human papillomavirus type 16 E6/E7-specific cytotoxic T lymphocytes for adoptive immunotherapy of HPV-associated malignancies.
|
Academic Article
|
Tumor necrosis factor mediates autocrine growth inhibition in a chronic leukemia.
|
Academic Article
|
Adoptive immunotherapy for Epstein-Barr virus-related lymphoma.
|
Academic Article
|
Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the treatment of patients with EBV-positive relapsed Hodgkin's disease.
|
Academic Article
|
Administration of neomycin resistance gene marked EBV specific cytotoxic T-lymphocytes to patients with relapsed EBV-positive Hodgkin disease.
|
Academic Article
|
Transfer of EBV-specific CTL to prevent EBV lymphoma post bone marrow transplant.
|
Academic Article
|
Administration of neomycin resistance gene-marked EBV-specific cytotoxic T-lymphocytes as therapy for patients receiving a bone marrow transplant for relapsed EBV-positive Hodgkin disease.
|
Academic Article
|
Phase I study of chemokine and cytokine gene-modified autologous neuroblastoma cells for treatment of relapsed/refractory neuroblastoma using an adenoviral vector.
|
Academic Article
|
Reconstitution of the T cell receptor alpha beta repertoire in recipients of allogeneic BMT.
|
Academic Article
|
Efficient infection of primitive hematopoietic stem cells by modified adenovirus.
|
Academic Article
|
Allogeneic bone marrow transplantation for children with histiocytic disorders: use of TBI and omission of etoposide in the conditioning regimen.
|
Academic Article
|
Complement-fixing CD45 monoclonal antibodies to facilitate stem cell transplantation in mouse and man.
|
Academic Article
|
Expansion of EBV latent membrane protein 2a specific cytotoxic T cells for the adoptive immunotherapy of EBV latency type 2 malignancies: influence of recombinant IL12 and IL15.
|
Academic Article
|
Immunotherapy of hematologic malignancy.
|
Academic Article
|
Possible mechanism of selective killing of myeloid leukemic blast cells by lymphokine-activated killer cells.
|
Academic Article
|
Prompt versus preemptive intervention for EBV lymphoproliferative disease.
|
Academic Article
|
Cytotoxic T lymphocyte therapy for Epstein-Barr virus+ Hodgkin's disease.
|
Academic Article
|
Cytomegalovirus (CMV) infections and CMV-specific cellular immune reconstitution following reduced intensity conditioning allogeneic stem cell transplantation with Alemtuzumab.
|
Academic Article
|
Adoptive T-cell transfer in cancer immunotherapy.
|
Academic Article
|
In vivo expansion of LMP 1- and 2-specific T-cells in a patient who received donor-derived EBV-specific T-cells after allogeneic stem cell transplantation.
|
Academic Article
|
Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer.
|
Academic Article
|
Requirements for the adoptive transfer of antibody responses to a priming antigen in man.
|
Academic Article
|
Cytotoxic T lymphocytes as immune-therapy in haematological practice.
|
Academic Article
|
The t(9;22) translocation in Philadelphia-positive essential thrombocythaemia does not involve the T lymphocyte lineage.
|
Academic Article
|
Nucleofection of DCs to generate Multivirus-specific T cells for prevention or treatment of viral infections in the immunocompromised host.
|
Academic Article
|
Derivation of human T lymphocytes from cord blood and peripheral blood with antiviral and antileukemic specificity from a single culture as protection against infection and relapse after stem cell transplantation.
|
Academic Article
|
Adoptive T cell therapy of cancer.
|
Academic Article
|
Safer CARS.
|
Academic Article
|
An inducible caspase 9 suicide gene to improve the safety of mesenchymal stromal cell therapies.
|
Academic Article
|
Production of good manufacturing practice-grade cytotoxic T lymphocytes specific for Epstein-Barr virus, cytomegalovirus and adenovirus to prevent or treat viral infections post-allogeneic hematopoietic stem cell transplant.
|
Academic Article
|
Spontaneous and interleukin 2 induced secretion of tumour necrosis factor and gamma interferon following autologous marrow transplantation or chemotherapy.
|
Academic Article
|
Plasma markers of B-cell activation and clonality in pediatric liver and hematopoietic stem cell transplant recipients.
|
Academic Article
|
Robust and cost effective expansion of human regulatory T cells highly functional in a xenograft model of graft-versus-host disease.
|
Concept
|
Antigens, Differentiation, T-Lymphocyte
|
Concept
|
Jurkat Cells
|
Concept
|
Lymphoma, T-Cell
|
Concept
|
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
Concept
|
Hematopoietic Stem Cells
|
Concept
|
Lymphocytes
|
Concept
|
Receptors, Antigen, T-Cell, alpha-beta
|
Concept
|
T-Lymphocytes, Cytotoxic
|
Concept
|
Receptors, Antigen, T-Cell
|
Concept
|
Neoplastic Stem Cells
|
Concept
|
T-Cell Antigen Receptor Specificity
|
Concept
|
HeLa Cells
|
Concept
|
Dendritic Cells
|
Concept
|
T-Lymphocytes, Helper-Inducer
|
Concept
|
HL-60 Cells
|
Concept
|
Clone Cells
|
Concept
|
K562 Cells
|
Concept
|
Th1 Cells
|
Concept
|
CD8-Positive T-Lymphocytes
|
Concept
|
Gene Rearrangement, beta-Chain T-Cell Antigen Receptor
|
Concept
|
Reed-Sternberg Cells
|
Concept
|
Endothelial Cells
|
Concept
|
Blood Cells
|
Concept
|
T-Lymphocytes, Regulatory
|
Concept
|
Induced Pluripotent Stem Cells
|
Concept
|
CD4-Positive T-Lymphocytes
|
Concept
|
Killer Cells, Lymphokine-Activated
|
Concept
|
Antigen-Presenting Cells
|
Concept
|
Th2 Cells
|
Concept
|
B-Lymphocytes
|
Concept
|
Leukemia-Lymphoma, Adult T-Cell
|
Concept
|
T-Lymphocyte Subsets
|
Concept
|
Tumor Cells, Cultured
|
Concept
|
Epitopes, T-Lymphocyte
|
Concept
|
Adult Stem Cells
|
Concept
|
Lymphocytes, Tumor-Infiltrating
|
Concept
|
Bone Marrow Cells
|
Concept
|
Myeloid Cells
|
Concept
|
Killer Cells, Natural
|
Concept
|
Plasma Cells
|
Concept
|
Cells, Cultured
|
Concept
|
Stem Cells
|
Concept
|
T-Lymphocytes
|
Concept
|
Receptors, Antigen, T-Cell, gamma-delta
|
Concept
|
Natural Killer T-Cells
|
Academic Article
|
Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation.
|
Academic Article
|
The immunogenicity of virus-derived 2A sequences in immunocompetent individuals.
|
Academic Article
|
Robust T cell responses to aspergillosis in chronic granulomatous disease: implications for immunotherapy.
|
Academic Article
|
Genetic engineering of T-cell receptors: TCR takes to titin.
|
Academic Article
|
Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study.
|
Academic Article
|
Combinational targeting offsets antigen escape and enhances effector functions of adoptively transferred T cells in glioblastoma.
|
Academic Article
|
Safety and clinical efficacy of rapidly-generated trivirus-directed T cells as treatment for adenovirus, EBV, and CMV infections after allogeneic hematopoietic stem cell transplant.
|
Academic Article
|
T-cell therapy for viral infections.
|
Academic Article
|
T lymphocytes targeting native receptors.
|
Academic Article
|
Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15.
|
Academic Article
|
Long-term outcome after haploidentical stem cell transplant and infusion of T cells expressing the inducible caspase 9 safety transgene.
|
Academic Article
|
Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins.
|
Academic Article
|
Reversal of tumor immune inhibition using a chimeric cytokine receptor.
|
Academic Article
|
Systemic inflammatory response syndrome after administration of unmodified T lymphocytes.
|
Academic Article
|
Ultra low-dose IL-2 for GVHD prophylaxis after allogeneic hematopoietic stem cell transplantation mediates expansion of regulatory T cells without diminishing antiviral and antileukemic activity.
|
Academic Article
|
Kinetics of tumor destruction by chimeric antigen receptor-modified T cells.
|
Academic Article
|
Antiviral T-cell therapy.
|
Academic Article
|
Immunotherapy: opportunities, risks and future perspectives.
|
Academic Article
|
Complementation of antigen-presenting cells to generate T lymphocytes with broad target specificity.
|
Academic Article
|
Activity of broad-spectrum T cells as treatment for AdV, EBV, CMV, BKV, and HHV6 infections after HSCT.
|
Academic Article
|
Reply to S. Yuan et al.
|
Academic Article
|
T-cell immunotherapy: looking forward.
|
Academic Article
|
Survivin-specific T cell receptor targets tumor but not T cells.
|
Academic Article
|
Graft versus leukemia response without graft-versus-host disease elicited by adoptively transferred multivirus-specific T-cells.
|
Academic Article
|
Human Epidermal Growth Factor Receptor 2 (HER2) -Specific Chimeric Antigen Receptor-Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma.
|
Academic Article
|
CMV-specific T cells generated from na?ve T cells recognize atypical epitopes and may be protective in vivo.
|
Academic Article
|
Optimizing the production of suspension cells using the G-Rex "M" series.
|
Academic Article
|
Clonal Dynamics In Vivo of Virus Integration Sites of T Cells Expressing a Safety Switch.
|
Academic Article
|
Inducible caspase-9 suicide gene controls adverse effects from alloreplete T cells after haploidentical stem cell transplantation.
|
Academic Article
|
Tumor indoleamine 2,3-dioxygenase (IDO) inhibits CD19-CAR T cells and is downregulated by lymphodepleting drugs.
|
Academic Article
|
Late-onset severe chronic active EBV in a patient for five years with mutations in STXBP2 (MUNC18-2) and PRF1 (perforin 1).
|
Academic Article
|
Antigen-specific T cell therapies for cancer.
|
Academic Article
|
CAR-T Cell Therapy for Lymphoma.
|
Academic Article
|
Clinical responses with T lymphocytes targeting malignancy-associated ? light chains.
|
Academic Article
|
Adoptive immunotherapy for primary immunodeficiency disorders with virus-specific T lymphocytes.
|
Academic Article
|
Forecasting Cytokine Storms with New Predictive Biomarkers.
|
Academic Article
|
Policy: Global standards for stem-cell research.
|
Academic Article
|
Serial Activation of the Inducible Caspase 9 Safety Switch After Human Stem Cell Transplantation.
|
Academic Article
|
Setting Global Standards for Stem Cell Research and Clinical Translation: The?2016 ISSCR Guidelines.
|
Academic Article
|
T cells for viral infections after allogeneic hematopoietic stem cell transplant.
|
Academic Article
|
Delayed Induction of Proto-Oncogene Expression in B-CLL Cells by Tumor Necrosis Factor.
|
Academic Article
|
Adoptive cellular therapy with T cells specific for EBV-derived tumor antigens.
|
Academic Article
|
Recent advances in T-cell immunotherapy for haematological malignancies.
|
Academic Article
|
Checkpoint inhibition and cellular immunotherapy in lymphoma.
|
Academic Article
|
Improving Chimeric Antigen Receptor-Modified T Cell Function by Reversing the Immunosuppressive Tumor Microenvironment of Pancreatic Cancer.
|
Academic Article
|
Fall of the mutants: T cells targeting BCR-ABL.
|
Academic Article
|
Exhausting alloreactivity of donor-derived CAR T cells.
|
Academic Article
|
Fine-tuning the CAR spacer improves T-cell potency.
|
Academic Article
|
HER2-Specific Chimeric Antigen Receptor-Modified Virus-Specific T Cells for Progressive Glioblastoma: A Phase 1 Dose-Escalation Trial.
|
Academic Article
|
CAR T Cells Administered in Combination with Lymphodepletion and PD-1 Inhibition to Patients with Neuroblastoma.
|
Academic Article
|
Equal opportunity CAR T cells.
|
Academic Article
|
Off-the-Shelf Virus-Specific T Cells to Treat BK Virus, Human Herpesvirus 6, Cytomegalovirus, Epstein-Barr Virus, and Adenovirus Infections After Allogeneic Hematopoietic Stem-Cell Transplantation.
|
Academic Article
|
Clinical and immunological responses after CD30-specific chimeric antigen receptor-redirected lymphocytes.
|
Academic Article
|
Tumor-Specific T-Cells Engineered to Overcome Tumor Immune Evasion Induce Clinical Responses in Patients With Relapsed Hodgkin Lymphoma.
|
Academic Article
|
The use of chimeric antigen receptor T cells in patients with non-Hodgkin lymphoma.
|
Academic Article
|
A backpack revs up T-cell activity.
|
Academic Article
|
Generation of multivirus-specific T cells by a single stimulation of peripheral blood mononuclear cells with a peptide mixture using serum-free medium.
|
Academic Article
|
Clinical Utilization of Chimeric Antigen Receptor T Cells in B Cell Acute Lymphoblastic Leukemia: An Expert Opinion from the European Society for Blood and Marrow Transplantation and the American Society for Blood and Marrow Transplantation.
|
Academic Article
|
Harmonizing Immune Effector Toxicity Reporting.
|
Grant
|
Anti-viral and antileukemic T-cell therapy as prophylaxis after HSCT
|
Grant
|
DOUBLE GENE MARKING TO ANALYZE STEM CELLS IN CHILDREN
|
Grant
|
ENHANCING T CELL THERAPY OF CANCER
|
Academic Article
|
In?Vivo Fate and Activity of Second- versus Third-Generation CD19-Specific CAR-T Cells in B Cell Non-Hodgkin's Lymphomas.
|
Academic Article
|
EBV/LMP-specific T cells maintain remissions of T- and B-cell EBV lymphomas after allogeneic bone marrow transplantation.
|
Academic Article
|
Adoptive Immunotherapy with Antigen-Specific T Cells Expressing a Native TCR.
|
Academic Article
|
Epigenetic Inhibition Puts Target Antigen in the Crosshairs of CAR T Cells.
|
Concept
|
HEK293 Cells
|
Academic Article
|
Clinical utilization of Chimeric Antigen Receptor T-cells (CAR-T) in B-cell acute lymphoblastic leukemia (ALL)-an expert opinion from the European Society for Blood and Marrow Transplantation (EBMT) and the American Society for Blood and Marrow Transplantation (ASBMT).
|
Academic Article
|
T-cell receptor sequencing demonstrates persistence of virus-specific T cells after antiviral immunotherapy.
|
Academic Article
|
"Mini" bank of only 8 donors supplies CMV-directed T cells to diverse recipients.
|
Academic Article
|
T-Cell Receptor Stimulation Enhances the Expansion and Function of CD19 Chimeric Antigen Receptor-Expressing T Cells.
|
Academic Article
|
CRISPR-Edited Immune Effectors: The End of the Beginning.
|
Academic Article
|
Engineered off-the-shelf therapeutic T cells resist host immune rejection.
|
Academic Article
|
Tumor response and endogenous immune reactivity after administration of HER2 CAR T cells in a child with metastatic rhabdomyosarcoma.
|
Academic Article
|
The safety and clinical effects of administering a multiantigen-targeted T cell therapy to patients with multiple myeloma.
|
Academic Article
|
Modulating TNFa activity allows transgenic IL15-Expressing CLL-1 CAR T cells to safely eliminate acute myeloid leukemia.
|
Academic Article
|
Clinical effects of administering leukemia-specific donor T cells to patients with AML/MDS after allogeneic transplant.
|
Academic Article
|
Adoptive T-Cell Therapy for Epstein-Barr Virus-Related Lymphomas.
|
Academic Article
|
T-Cell Therapy for Lymphoma Using Nonengineered Multiantigen-Targeted T Cells Is Safe and Produces Durable Clinical Effects.
|
Academic Article
|
Taking T-Cell Oncotherapy Off-the-Shelf.
|
Academic Article
|
Virus-specific T cells for malignancies - then, now and where to?
|
Academic Article
|
Demographic and Clinical Donor Characteristics as Predictors of Total Nucleated Cell Concentrations in Harvested Marrow Products.
|
Academic Article
|
Autologous EBV-specific T cell treatment results in sustained responses in patients with advanced extranodal NK/T lymphoma: results of a multicenter study.
|
Academic Article
|
Scalable Manufacturing of CAR T cells for Cancer Immunotherapy.
|
Academic Article
|
High risk of relapsed disease in patients with NK/T-cell chronic active Epstein-Barr virus disease outside of Asia.
|
Academic Article
|
Beyond CD19 CAR-T cells in lymphoma.
|
Academic Article
|
Donor-derived multiple leukemia antigen-specific T-cell therapy to prevent relapse after transplant?in patients with ALL.
|
Academic Article
|
Multi-antigen-targeted T-cell therapy to treat patients with relapsed/refractory breast cancer.
|
Academic Article
|
Tumor-intrinsic causes of CAR-T failure.
|
Academic Article
|
Feasibility and preclinical efficacy of CD7-unedited CD7 CAR T?cells for T?cell malignancies.
|
Academic Article
|
Engineering T cells to suppress acute GVHD and?leukemia relapse after allogeneic hematopoietic stem cell transplantation.
|
Academic Article
|
Posoleucel, an Allogeneic, Off-the-Shelf Multivirus-Specific T-Cell Therapy, for the Treatment of Refractory Viral Infections in the Post-HCT Setting.
|
Academic Article
|
Secreted Fas Decoys Enhance the Antitumor Activity of Engineered and Bystander T Cells in Fas Ligand-Expressing Solid Tumors.
|
Academic Article
|
Allogeneic, off-the-shelf, SARS-CoV-2-specific T cells (ALVR109) for the treatment of COVID-19 in high-risk patients.
|
Academic Article
|
Introduction to a review series on banked allogeneic immune effector cells.
|
Academic Article
|
Paving the Road for Chimeric Antigen Receptor T Cells: American Society for Transplantation and Cellular Therapy 80/20 Task Force Consensus on Challenges and Solutions to Improving Efficiency of Clinical Center Certification and Maintenance of Operations for Commercially Approved Immune Effector Cell Therapies.
|
Academic Article
|
Introduction to a How I Treat series on emergent CAR T-cell toxicities.
|
Academic Article
|
Naive T cells inhibit the outgrowth of intractable antigen-activated memory T cells: implications for T-cell immunotherapy.
|
Academic Article
|
A robust quality infrastructure is key to safe and effective delivery of immune effector cells: how FACT-finding can help.
|
Academic Article
|
Moving CAR-Ts to the outpatient clinic.
|
Academic Article
|
Antitumor efficacy and safety of unedited autologous CD5.CAR T cells in relapsed/refractory mature T-cell lymphomas.
|
Academic Article
|
Long-Term Follow-Up for Recipients of Genetically Modified Cells: A Team Effort.
|
Academic Article
|
Human platelet lysate enhances in vivo activity of CAR-Vd2 T cells by reducing cellular senescence and apoptosis.
|